This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Docosahexaenoic acid, found lacking in animal models of cystic fibrosis, has been proposed as a dietary supplement therapy for this genetic disorder. Alpha-fetoprotein, which binds and transports docosahexaenoic acid, may be a useful marker to improve the management and follow-up in newborn screening programs for cystic fibrosis, because only 20% of such infants are diagnosed at birth.
- cystic fibrosis newborn screening
- alpha-fetoprotein dietary supplement
- fatty acids docosahexaenoic acid
- Received July 14, 2001.
- Accepted July 25, 2001.
- American Academy of Pediatrics
Individual Login
Log in
You will be redirected to aap.org to login or to create your account.
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Related Articles
Cited By...
- No citing articles found.